文献速递外周动脉疾病血液透析通路

经导管深静脉动脉化治疗无选择CLTI后截肢与死亡的不同时间模式

Distinct Temporal Patterns of Limb Loss and Mortality After Transcatheter Arterialization of the Deep Veins for No-Option CLTI.
PubMed 文献 · Ann Vasc Surg · 2026-10-14

本研究回顾性纳入29例接受经导管深静脉动脉化(TADV)的无选择慢性肢体威胁性缺血(CLTI)患者,随访至2年。技术成功率为100%,保肢率为75.9%,全因死亡率为41.4%;截肢几乎均发生在术后最初数月内,而死亡风险随随访持续上升。

要点

  • TADV技术成功率高,2年保肢率约四分之三。
  • 大截肢集中于术后早期,后期保肢曲线趋于平台。
  • 全因死亡率随随访持续升高,高龄与死亡相关。

核心结论

  • TADV在无选择CLTI患者中实现约四分之三患者至2年的持久保肢,截肢几乎仅发生于术后最初数月内。
  • 全因死亡在整个随访期间持续存在且比例较高,与该人群合并症负担一致。
  • 研究支持TADV作为无选择CLTI患者的保肢选择,但需更大规模多中心研究确认长期耐久性。

研究设计与样本

  • 单中心回顾性队列研究,连续纳入29例接受TADV的无选择CLTI患者,随访延长至2年。
  • 评估指标包括技术成功、30天回路通畅、大截肢、保肢、全因死亡和无截肢生存(AFS)。
  • 采用Kaplan-Meier法估计时间事件结局,单变量Cox回归识别与AFS和死亡相关的基线因素。

主要发现

  • 全部29例患者技术成功(100%)。
  • 随访期间22/29例(75.9%)维持保肢。
  • Kaplan-Meier保肢曲线在约7个月后趋于平台,此后无大截肢发生。
  • 全因死亡率为41.4%(12/29例),且随随访持续升高。
  • 较高年龄与死亡显著相关(中位77岁 vs 71岁;P = .047),充血性心力衰竭呈死亡风险升高的非显著趋势(83.3% vs 47.1%;P = .064)。

关键数值与推荐

  • 单中心队列报告保肢率75.9%(22/29),全因死亡率41.4%(12/29)。
  • 年龄与死亡相关:中位77岁 vs 71岁,P = .047。
  • 充血性心力衰竭与死亡:83.3% vs 47.1%,P = .064(非显著趋势)。
  • 背景提及标准治疗下1年无截肢生存(AFS)约37%。

临床怎么用

  • 对无选择CLTI患者,TADV可作为替代大截肢的保肢策略。
  • 术后最初数月是截肢高风险窗口,需密切监测回路与肢体状态。
  • 高龄及合并心力衰竭患者死亡风险较高,应加强围术期与长期内科管理。

局限性

  • 单中心回顾性设计,样本量仅29例。
  • 随访至2年,长期耐久性仍需更大规模多中心研究确认。
  • 单变量分析,未充分校正混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: No-option chronic limb-threatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease, characterized by exhausted revascularization options and substantial systemic comorbidity. Contemporary registry data have reported amputation-free survival (AFS) as low as approximately 37% at 1 year with standard care alone. Deep venous arterialization (DVA) has emerged as a limb-salvage strategy for these patients by arterializing the venous circulation to restore perfusion to the distal extremity. Although early trial data have been encouraging, the durability of Transcatheter Arterialization of the Deep Veins (TADV) in routine clinical practice beyond the trial setting remains incompletely defined. We evaluated 2-year technical and clinical outcomes following TADV in a single-center cohort. METHODS: We performed a retrospective, single-center cohort study of 29 consecutive patients with no-option CLTI who underwent TADV, with follow-up extending up to 2 years. Outcomes assessed included technical success, 30-day circuit patency, major amputation, limb salvage, all-cause mortality, and amputation-free survival (AFS). Kaplan-Meier methods were used to estimate time-to-event outcomes, and univariable Cox regression was used to identify baseline factors associated with AFS and mortality. RESULTS: Technical success was achieved in all 29 patients (100%). During the follow-up, limb salvage was maintained in 22 of 29 patients (75.9%) (Table 2). The Kaplan-Meier limb-salvage curve plateaued after approximately 7 months, with no major amputations observed among patients who remained amputation-free beyond this point (Figure 1). All-cause mortality was 41.4% (12 of 29 patients) and increased throughout follow-up (Table 2). Older age was significantly associated with mortality (median, 77 vs 71 years; P = .047), and congestive heart failure showed a nonsignificant trend toward increased mortality risk (83.3% vs 47.1%; P = .064) (Table 3). CONCLUSIONS: In this cohort of patients with no-option CLTI, TADV achieved durable limb preservation in approximately three-quarters of patients through 2 years of follow-up, with amputation occurring almost exclusively within the first several months after the procedure. All-cause mortality remained substantial throughout follow-up, consistent with the comorbidity burden of this population. These findings support TADV as a limb-salvage option for patients with no-option CLTI who would otherwise face major amputation, although larger multicenter studies are needed to confirm long-term durability.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bhatt S, Sheshdeh AB, Bansal R, et al. Distinct Temporal Patterns of Limb Loss and Mortality After Transcatheter Arterialization of the Deep Veins for No-Option CLTI. Ann Vasc Surg. 2026. PMID: 42874861. doi:10.1016/j.avsg.2026.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。